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PLATELETS AND THROMBOPOIESIS
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Platelets are highly specialized blood cells
critically involved in hemostasis and
thrombosis. Members of the protein ki-
nase C (PKC) family have established
roles in regulating platelet function and
thrombosis, but the molecular mecha-
nisms are not clearly understood. In par-
ticular, the conventional PKC isoform,
PKC, is a major regulator of platelet
granule secretion, but the molecular path-
way from PKC to secretion is not de-
fined. Protein kinase D (PKD) is a family
of 3 kinases activated by PKC, which may
represent a step in the PKC signaling
pathway to secretion. In the present study,
we show that PKD2 is the sole PKD mem-
ber regulated downstream of PKC in plate-
lets, and that the conventional, but not
novel, PKC isoforms provide the up-
stream signal. Platelets from a gene
knock-in mouse in which 2 key phosphor-
ylation sites in PKD2 have been mutated
(Ser707Ala/Ser711Ala) show a significant
reduction in agonist-induced dense
granule secretion, but not in -granule
secretion. This deficiency in dense
granule release was responsible for a
reduced platelet aggregation and a
marked reduction in thrombus formation.
Our results show that in the molecular
pathway to secretion, PKD2 is a key com-
ponent of the PKC-mediated pathway to
platelet activation and thrombus forma-
tion through its selective regulation of
dense granule secretion. (Blood. 2011;
118(2):416-424)
Introduction
Platelet activation underlies the arterial thrombosis that causes the
acute severe symptoms of heart disease and thrombotic stroke,1 and
it is therefore important to determine the molecular mechanisms
regulating platelet activity. We and others have shown that protein
kinase C (PKC) isoforms regulate all of the essential functions of
platelets, including actin rearrangements, adhesion through integ-
rins, and secretion of granule contents.2-6 Of the isoforms of PKC
expressed in platelets, the conventional PKCs, PKC and PKC,
have clear positive signaling roles, and mouse platelets lacking
expression of PKC show marked attenuation of responses and
thrombus formation.2,7 The critical function regulated by PKC is
the secretion of dense granule content, which is rescued by the
addition of exogenous ADP.2 Therefore, we sought to identify
proteins that lie downstream of PKC in the pathway to regulation of
dense-granule secretion to investigate the molecular regulation of
this essential function.
The protein kinase D (PKD) family of Ser/Thr kinases consists
of 3 members, PKD1 (also known as PKC), PKD2 and PKD3.8
PKDs contain a tandem repeat of zinc finger–like cysteine-rich
motifs at their N-termini, highly homologous to domains found in
diacylglycerol (DAG)/phorbol ester–sensitive PKCs and other
signaling proteins regulated by DAG. However, unlike PKCs,
PKDs lack the C2 domain responsible for the Ca2 sensitivity of
conventional PKCs, whereas they possess an autoinhibitory PH
domain. Further, the catalytic domain of PKD has low homology
with the conserved kinase domain of the PKCs. These differences
make the PKD family a distinct set of kinases.
We were interested in PKDs because they had been shown to be
activated in a PKC-dependent manner in a range of cells in
response to a variety of stimuli.8-10 It has been proposed that DAG,
which is generated by phospholipase C activation, binds to zinc
finger 2 of the PKD N-terminus and facilitates the recruitment of
the kinase to the plasma membrane, where it may be phosphory-
lated by PKCs. Residues Ser744 and Ser748 in the activation loop
of PKD1 (conserved in PKD2/3) have been shown to be the critical
sites for PKC-dependent PKD activation, leading to subsequent
autophosphorylation of other residues such as Ser916.8 PKD2 may
be activated by PKC through the cholecystokinin b/gastrin
receptor in human gastric carcinoma cells11 and during the process
of angiotensin-induced endothelial cell exocytosis.12
A study by Stafford et al13 revealed the expression of PKD in
platelets, and pharmacologic evidence suggested that PKD may be
activated in a PKC-dependent manner. However, the high degree of
homology between PKD1 and PKD2 means that the antibody used
in this study was not able to distinguish between these 2 isoforms,
and furthermore the expression of PKD3 was not addressed. The
function of PKD in platelets was also not investigated in that study.
However, with the generation of novel mutant mice this has now
become possible. According to the comprehensive dataset for gene
expression in blood cells, HaemAtlas, mRNA for PKD1 is absent
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from the human platelet precursor megakaryocytes, but PKD2 and
PKD3 are present at the transcript level.14 To evaluate isoform-
specific involvement of PKD in the regulation of essential platelet
functions, we used PKD2 gene-trapped knockout mice described
recently,9 and were able to confirm the expression of PKD2 and
PKD3 and the absence of PKD1 in mouse platelets. Using mice
generated with mutations in the PKC-dependent phosphorylation
sites in PKD2 (Ser707/Ser711), PKD2SSAA/SSAA knock-in mice, we
show that PKD2 is the exclusive PKD isoform that fulfils the role
of PKC substrate in platelets, whereas PKD3 is not regulated
downstream of PKC. We also elucidate the cellular function of
PKD2 downstream of PKC activation using platelets from the
PKD2SSAA/SSAA mouse. Using this approach, we show that PKD2
has a distinct role in selectively regulating dense-granule secretion,
but not -granule secretion, and in turn regulates thrombosis. We
have therefore demonstrated PKD2 to be a major effector of PKC,
particularly of PKC, mediating its dense granule secretory
function and subsequently thrombus formation.
Methods
Materials
The glycoprotein VI (GPVI)–specific agonist collagen-related peptide
(CRP) was provided by Richard Farndale (University of Cambridge,
Cambridge, United Kingdom). Thrombin, BSA, ADP, protein G-Sepharose,
GF109203X, fibrinogen, sodium orthovanadate, 2-glycerophosphate, PMSF,
and sodium fluoride were purchased from Sigma-Aldrich. Complete Mini
Protease Inhibitor tablets were from Roche Applied Science. Secondary
horseradish peroxidase-conjugated anti–rabbit antibody was obtained from
Amersham. JON/A (anti-IIb3), WugE9 (anti–P-selectin), and JAQ-1
(anti-GPVI) antibodies were from Emfret Analytics. Phycoerythrin-
conjugated anti-CD41 antibody and its isotype-matched control, PE-
conjugated rat IgG1, were from AbD Serotec. PKC rabbit polyclonal
antibody was BD Biosciences. Alexa Fluor 647, Annexin A5 and Count-
Bright counting beads were from Invitrogen. PKCII rabbit, PKD2 goat,
and PKC polyclonal rabbit antibodies were from Santa Cruz Biotechnolo-
gies. P-PKD (Ser 916) and P-PKD (Ser916) rabbit polyclonal antibodies
were from Cell Signaling Technologies. PKD3 rabbit polyclonal was an
in-house antibody. LY333531 was supplied by A.G. Scientific. CHRONO-
LUME reagent came from Chrono-log (Labmedics).
Mouse platelet preparation
Gene-trapped PKD2/ and knockin PKD2SSAA/SSAA mice were generated
as described previously.9 Mice were bred and maintained in the University
of Bristol animal facility in accordance with United Kingdom Home Office
regulations. All procedures were undertaken with United Kingdom Home
Office approval in accordance with the Animals (Scientific Procedures) Act
of 1986 (project license numbers: 40/2212, 40/2749, and 30/2386). Blood
was drawn by cardiac puncture under terminal anesthesia into acid citrate
dextrose (20mM citric acid, 110mM sodium citrate, and 5mM glucose) at a
1:7 ratio (vol/vol). Platelets were prepared as described previously.15
In brief, blood was diluted with 250 L of modified Tyrode HEPES
buffer (134mM NaCl, 0.34mM Na2HPO4, 2.9mM KCl, 12mM NaHCO3,
20mM HEPES, 5mM glucose, and 1mM MgCl2, pH 7.3) and centrifuged at
180g for 6 minutes at room temperature. Platelet-rich plasma was removed
and platelets were isolated by centrifugation at 550g for 6 minutes in the
presence of PGE1 (140nM) and indomethacin (10M). Pelleted platelets
were resuspended to the required density in modified Tyrode HEPES buffer,
and rested for 30 minutes at 37°C in the presence of 10M indomethacin
before stimulation.
Human platelet preparation
Blood was obtained from healthy drug-free volunteers in accordance with
approved guidelines from the Local Research Ethics Committee of the
University of Bristol. Informed consent was obtained in accordance with
the Declaration of Helsinki. Indomethacin (10M) was added to PRP and
throughout subsequent preparation steps.
Platelet aggregation
Platelets were resuspended in Tyrode HEPES buffer at a final concentration
of 2  108/mL. Aggregation of agonist-stimulated platelets was monitored
in an optical aggregometer (Chrono-log; Labmedics) at 37°C, with
continuous stirring at 800 revolutions per minute.
Flow cytometry
Two-color analysis of mouse platelet activation was conducted using
PE-conjugated JON/A, an antibody that preferentially binds to the active
form of IIb3 integrin, and with a FITC-conjugated antibody specific for
CD62P (P-selectin). Twenty-five microliters of washed platelets (4  107/mL
in Tyrode HEPES buffer) was mixed with 10 L of antibody and
subsequently stimulated either with CRP (5 g/mL) or thrombin (1 unit/mL) for
15 minutes at room temperature. The reaction was stopped by the addition
of 400 L ice-cold PBS, and samples were analyzed within 30 minutes. For
estimation of surface expression of IIb3, platelets were stained with
PE-conjugated anti-CD41. Annexin V-FITC was used to detect surface
phosphatidylserine exposure. Platelets (5  107/mL) were stimulated in the
presence of CaCl2 (2mM) for 10 minutes. For flow cytometry platelets were
gated by their forward and side scatter profile. Flow cytometry was
performed on a FACSCalibur flow cytometer (BD Biosciences), using
CellQuest software Version 3.1f (BD Biosciences), and a total of
20 000 events per sample were collected. Data were analyzed using
WinMDI Version 2.8.
Measurement of ATP secretion
ATP secretion was measured using CHRONO-LUME reagent according to
the manufacturer’s protocol. Five microliters of luciferase-luciferin was
added directly to the platelets, which were being continuously stirred
(1000 revolutions per minute), and CRP or thrombin at various concentra-
tions were added to activate platelets for 1 minute. The luminescence
intensity was measured at a setting of 0.05.
Platelet static adhesion assay
Coverslips were coated with either fibrinogen (0.1 mg/mL) or CRP
(5 g/mL) and left overnight, followed by nonspecific blocking with
2% BSA for 1 hour. For spreading experiments, coverslips were coated with
CRP (5 g/mL) or mouse fibrinogen (100 g/mL) overnight at 4°C. After
twice washing with PBS, coverslips were blocked with 1% fatty acid–free
BSA in PBS for 2 hours at room temperature and then rinsed with PBS.
BSA-coated coverslips were used a negative control. Washed murine
platelets (107/mL) were plated on coverslips for 20 minutes at room
temperature. After washing of unbound platelets, the adherent platelets
were fixed with 4% paraformaldehyde for 20 minutes at 4°C. After the final
wash, platelets were visualized with a Leica DMIRBE inverted microscope.
Fifteen to 20 images in randomly chosen areas of the coverslip were
captured using OpenLab 4.03 (Improvision) software, and the number
of adherent platelets was estimated using ImageJ software
(http://rsbweb.nih.gov/ij/).
Immunoblotting
For stimulated samples, 2  108/mL of washed platelets were preincubated
with different inhibitors or vehicle solution (0.1% DMSO final concentra-
tion) for 10 minutes at 37°C and subsequently activated with CRP or
thrombin at various concentrations and were solubilized in an equal volume
of SDS-Laemmli sample buffer. For immunoprecipitation assays platelets
were lysed into an equal volume of 2  lysis buffer (50mM HEPES, pH
7.4, 150mM NaCl, 2% (vol/vol) Triton X-100, 1mM sodium orthovanadate,
4mM PMSF, 20mM 2-glycerophosphate, 200mM sodium fluoride, 200mM
benzamidine, and complete protease inhibitors). Incubations with immuno-
precipitating antibody were carried out overnight at 4°C, beads were
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washed 3 times in 1  lysis buffer, and bound proteins were eluted by the
addition of SDS-sample buffer. Proteins were resolved by electrophoresis in
7% SDS-PAGE. Samples were then transferred to PVDF membranes,
blocked with 10% BSA, and subjected to immunoblotting with various
antibodies as described in the figure legends.
Thrombus formation under flow in vitro
Flow-induced thrombus formation was assessed essentially as described
previously.16 Heparin/D-phenylalanyl-prolyl-arginyl chloromethyl ketone
(PPACK)–anticoagulated mouse blood was passed over immobilized
collagen through a parallel plate perfusion chamber at a shear rate of 1000/s
for 4 minutes. For each perfusion surface, phase-contrast images from
10 random microscopic fields were collected. Surface coverage was
analyzed using Image-Pro software Version 4.1 (Media Cybernetics). The
average percentage area covered by adherent platelets was measured by
automated setting of masks for the ranges of gray levels corresponding to
the presence of platelets and thrombi. For each image, the (blinded)
observer needed to approve the mask settings. Averaged pixel fractions of
the masks from 10 images were considered as a best estimate of the surface
area coverage with thrombi.
Electron microscopy
Platelet samples from WT and PKD2SSAA/SSAA mice were prepared for
transmission electron microscopy, as described previously.2 Numbers of
dense granules and -granules in equivalent-sized fields of view were
counted using ImageJ software. For each genotype, 25-30 randomly chosen
fields of view were examined. All microscopic images were taken at the
same magnification (19 000), and the number of cells per field of view
between wild-type (WT) and PKD2SSAA/SSAA preparations were equivalent.
Analysis of bleeding time
Experiments were conducted on 25-35 g male and female mice. Mice were
anesthetized (75 mg/kg ketamine and 1 mg/kg medetomidine intraperitone-
ally), and a transverse incision was made with a scalpel at a position where
the diameter of the tail was 2.25-2.5 mm. The tail was immersed in normal
saline (37°C) in a hand-held test tube, and the time from incision to
cessation of bleeding was recorded.
Platelet count
To determine platelet count, 2-L blood samples were taken from the tail
vein and added to 43 L of ACD/Tyrode buffer (1:5 vol/vol). The blood
samples were incubated with anti–CD41:FITC antibody (1:10) for
20 minutes at room temperature in the dark. Blood samples were mixed
with 50 L of CountBright beads in 400 L of filtered Tyrode buffer
(following the manufacturer’s guidelines) before analysis on a FACSCali-
bur flow cytometer (BD Biosciences). Anti–CD41:FITC-labeled platelet
and CountBright bead populations were gated in a FL1 versus FL2 channel
dot-plot. The triplicate counts were averaged and the platelet count per
microliter of whole blood was calculated according to the manufacturer’s
instructions.
Results
Regulation of PKD by PKC isoforms in human and mouse
platelets
Previous studies showed that PKD activation in platelets via GPVI
and PAR-receptors is dependent on PKC,4 but the identity of the
PKC isoform(s) responsible has not been determined. We have
addressed this using pharmacologic and genetic approaches. Figure
1A shows that the robust and rapid autophosphorylation of PKD on
Ser916 and on the PKC-dependent Ser744 site by thrombin and
CRP in human platelets could be completely inhibited by a
broad-spectrum PKC inhibitor (GF109203X) or by the PKC-
selective inhibitor LY333531. Although a minor and faint band
appears slightly higher than the major band in pSer916 blots, this is
unlikely to represent PKD because reprobing with the PKD1/2
antibody only revealed a single band. Figure 1B shows that
pretreatment of platelets with LY333531 (10M) produced a
maximal inhibitory effect on thrombin-induced PKD activation.
Recent evidence has suggested that PKC may also be targeted by
LY333531, in addition to PKC,17 so we determined the activation
of PKD in platelets from PKC-deficient mice. Within the range of
agonist concentrations tested, thrombin was able to induce PKD
phosphorylation on Ser916 in WT platelets, particularly at the
highest concentration used (1 unit/mL; Figure 1C), although there
was still a small but measurable activation of the kinase at the lower
concentrations. This small degree of activation may explain the
small defect in aggregation response (seen later in Figure 5) using
thrombin at 0.065 units/mL. CRP induced a maximal response at
5 g/mL, and this was the concentration subsequently used
throughout the study (Figure 1C). PKC/ platelets showed a
substantially reduced level of CRP-induced PKD phosphorylation
on Ser916 compared with WT, although for thrombin there was no
significant change in phosphorylation. This may indicate that, for
thrombin, there is significant redundancy between PKC and
PKC in mediating phosphorylation of PKD, whereas for CRP
there is much less redundancy, with PKC taking the principal role.
With regard to the novel family of PKC isoforms, ablation of PKC
produced no change in agonist activation of PKD (Figure 1C),
whereas ablation of PKC caused a small potentiation of activation
of PKD activity in response to CRP. These data indicate that the
classical PKC isoforms PKC and PKC are likely to be positive
regulators of PKD, but that the novel isoform PKC is a negative
regulator. In addition, PKC has no role in regulating PKD activity,
especially downstream of GPVI activation.
PKD expression and activation profile in mouse platelets
The analysis of the expression and activation profile of PKD
isoforms in platelets was conducted using WT and PKD2-knockout
mice. Because of the high degree of homology between PKD1 and
PKD2, there is no antibody available that will distinguish between
the 2, and therefore we used an antibody (PKD1/2) raised against
the C-terminus of human and mouse PKD1 and PKD2. Figure
2A shows that there is no signal from PKD2/ platelets, whereas
an anti-PKD3 blot demonstrates expression of this isoform. We
conclude therefore that mouse platelets express PKD2 and PKD3,
but not PKD1, and that expression of PKD3 remained unaffected
by gene deletion of PKD2. Figure 2A also shows that phosphoryla-
tion of the PKC sites in the PKDs (indicated as S744/S748, because
the antibody relates to PKD1; however, these sites are conserved
between PKD2, at S707/S711, and PKD3, at S731/S735) and
Ser916 is restricted to PKD2 and not PKD3. Thus, although both
PKD2 and PKD3 are expressed in platelets, it is only PKD2 that is
activated upon agonist stimulation.
PKD2 activity in PKD2SSAA/SSAA mice is abolished
Phosphorylation by PKC at Ser707/Ser711 of PKD2, which may be
detected using the phosphospecific antiphospho-Ser744/Ser748
antibody for PKD1, is correlated with the activation status of the
kinase. Immunoblotting with antiphospho-Ser744/Ser748 demon-
strated that mutation of the 2 equivalent Ser in PKD2 eliminated
phosphorylation on these sites (Figure 2B). Analysis of activity of
PKD2 by assessment of phospho-Ser916 showed that whereas
phosphorylation of PKD2 in WT was greatly increased by agonist
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stimulation, no increase was seen in PKD2SSAA/SSAA platelets,
indicating that PKD2 kinase activity in platelets was eliminated by
these point mutations. This also indicated that agonist-induced
activation of PKD2 in platelets is mediated solely by PKC. The
presence of bands detected by antiphospho-Ser744/Ser748 and
Ser916 antibodies in lysates of basal platelets may be a result of
low-affinity cross-reactivity with nonphosphorylated PKD2 or
PKD3. Alternatively, we cannot rule out the possibility that PKD3
is constitutively phosphorylated and therefore basally active, which
would also explain the presence of bands under basal conditions.
However, the fact that no increase in band density was seen upon
stimulation would indicate that this is not a regulated activation. In
addition, there was no change in the expression levels of the PKC
isoforms found predominantly in mouse platelets (PKC, PKC,
PKC, and PKC) in PKD2SSAA/SSAA compared with WT platelets
(supplemental Figure 1, available on the Blood Web site; see the
Supplemental Materials link at the top of the online article).
PKD2 does not directly regulate integrin IIb3
Our results show that the PKD2SSAA/SSAA mouse provides an ideal
model for the study of the role played by PKD2 downstream of
classic PKC isoforms. We showed previously that ablation of
PKC causes a significant reduction in the ability of agonists to
activate integrin IIb32, so we could now address whether activa-
tion of PKD2 by PKC may form the signaling pathway. However,
as supplemental Figure 2 shows, the maximally effective concentra-
tions (as determined by PKD phosphorylation on Ser916; Figure
1C) of both CRP (5 g/mL; supplemental Figure 2Ai) and
thrombin (1 unit/mL; supplemental Figure 2Aii) produced similar
levels of IIb3 activation in both PKD2SSAA/SSAA and WT murine
platelets. As a control, supplemental Figure 3 shows no significant
difference in surface expression of IIb (CD41) or GPVI in
PKD2SSAA/SSAA compared with WT. The role of PKD2 in integrin
outside-in signaling was studied by assessing static adhesion to either
CRP or fibrinogen. The number of platelets measured at a fixed time
point demonstrated no difference between PKD2SSAA/SSAA and
WT platelets (supplemental Figure 2B). There were also no
differences in spreading on these surfaces between PKD2SSAA/SSAA
and WT platelets (data not shown). These observations suggest that
PKD2 does not directly mediate PKC-dependent signaling to
IIb3 activation.
PKD2 regulates dense- but not -granule secretion
Figure 3 demonstrates that PKD2SSAA/SSAA platelets exhibit a
marked reduction, although not a complete ablation, of CRP- and
thrombin-induced ATP secretion relative to WT controls. At a range
of agonist concentrations, a statistically significant reduction in
ATP levels in PKD2SSAA/SSAA was obtained even at the highest
concentrations of CRP (10 g/mL) and thrombin (1 unit/mL).
Interestingly, this defect in platelet exocytosis was restricted to
dense granules, because there were no differences in the degree of
P-selectin surface expression, which is used as an indicator of
-granule secretion, between WT and PKD2SSAA/SSAA platelets
(supplemental Figure 4) in response to CRP (5 g/mL) or thrombin
Figure 1. Agonist-induced PKD activation in platelets is dependent on classic PKC isoforms but independent of novel PKC isoforms. (A) Washed human platelets
(2  108/mL) were incubated with GFX (10M), LY333531 (10M), or vehicle (DMSO) for 10 minutes and subsequently stimulated with CRP (5 g/mL) or thrombin (1 unit/mL)
for 1 minute. (B) Washed human platelets (2  108/mL) were incubated with various concentrations of LY333531 or vehicle (DMSO) for 10 minutes and subsequently
stimulated with thrombin (1 unit/mL) for 1 minute under stirring conditions. Immunoblots were performed with P-PKD (Ser916), P-PKD (Ser744), or total PKD antibody. One
representative experiment of 3 with identical results is shown. (C) Washed platelets (2  108/mL) from WT, PKC/, PKC/, or PKC/ mice, were incubated with various
concentrations of CRP or thrombin for 1 minute. Immunoblots were performed with either P-PKD (Ser916) or total PKD antibody. One representative experiment (i) and
densitometric analysis of 3 experiments (ii) are shown. For panel Cii, data shown are means 	 SEM (n 
 3).
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(1 unit/mL). Quantification of the numbers of dense and -granules
by transmission electron microscopy did not reveal any significant
differences between the 2 groups of platelets (Figure 4). This shows
that in the absence of catalytically active PKD2, granule biogenesis
is not defective and therefore cannot be the cause of the impaired
dense granule secretion.
PKD2SSAA/SSAA platelets show impaired aggregation that may be
rescued by exogenous ADP
We showed previously that PKC deficiency causes a severe
reduction in the ability of platelets to aggregate, principally due to a
dysfunction at the level of dense-granule secretion.2 In the present
study, although a significant component of dense-granule secretion
remained in PKD2SSAA/SSAA mice, there was still a marked decrease
in platelet aggregation in response to submaximal concentrations of
CRP or thrombin (Figure 5). These responses to submaximal
concentrations of agonists (1.25 g/mL of CRP and 0.065 units/mL
of thrombin) could be effectively rescued by the simultaneous
addition of exogenous ADP (10M). Higher concentrations of
agonists showed no deficit in aggregation, indicating that the effect
is dependent on the degree of platelet activation through secondary
positive feedback mediators (data not shown).
PKD2SSAA/SSAA platelets show impaired thrombus formation in
vitro, but PKD2SSAA/SSAA mice retain a normal hemostatic
response
Perfusion of PPACK-anticoagulated whole blood from WT mice at
a high wall shear rate (1000/s) over a collagen-coated surface
resulted in rapid platelet adhesion, followed by the formation of
aggregates (Figure 6A) and exposure of procoagulant phosphatidyl-
serine (supplemental Figure 5). Although the initial adhesion of
PKD2SSAA/SSAA platelets remained unaffected, similar to that in
static adhesion experiments to CRP or fibrinogen (supplemental
Figure 2B), the subsequent thrombus formation was significantly
reduced. The thrombus surface coverage for PKD2SSAA/SSAA blood,
as a percentage of total area, was 15.71% 	 0.82% compared with
29.52% 	 2.71% (n 
 6, P  .002) for WT (Figure 6A, i-ii).
Procoagulant activity of PKD2SSAA/SSAA platelets in whole blood
under flow, as determined by Annexin V binding, was unimpaired
(supplemental Figure 5A); this was confirmed in platelets under
static conditions by flow cytometry (supplemental Figure 5B).
PKD2SSAA/SSAA mice exhibit normal hemostatic function, as
assessed by tail-vein bleeding experiments (Figure 6B). Given that
these animals have normal blood platelet counts (WT
1.14 	 0.09  106/L; PKD2SSAA/SSAA 1.21 	 0.17  106/L,
P  .05, n 
 5), this suggests that, as demonstrated previously for
PKC/ platelets,2 normal hemostasis may operate even under
conditions in which thrombus formation is impaired, suggesting a
clear distinction between the 2 processes.
Discussion
PKC plays a central role in the complex network of platelet signal
transduction. It has been shown previously that several members of
the family of PKC isoforms have distinct nonredundant roles in
Figure 2. PKD expression and activation profile in platelets. Washed platelets
from WT, PKD2/ (A), or PKD2SSAA/SSAA (B) mice (2  108/mL) were incubated with
CRP (5 g/mL) or thrombin (1 unit/mL) for 1 minute under stirring conditions.
Platelets were then solubilized in Laemmli sample buffer and whole cell lysates were
subjected to SDS-PAGE, transferred to PVDF membrane, and immunoblotted with
PKD1/2, PKD3, P-PKD (Ser916), or P-PKD (Ser744) antibodies. Data shown are
representative of 3 independent experiments.
Figure 3. PKD2 regulates secretion of dense granules in response to CRP and
thrombin in platelets. Washed platelets from WT and PKD2SSAA/SSAA mice were
stimulated with various concentrations of CRP (A) or thrombin (B) as indicated, and
secretion of ATP was assessed by luminometry. Error bars represent SEM, n 
 3-6;
*P  .05
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regulating essential platelet processes such as granule secretion,
integrin activation, aggregation, spreading, and procoagulant activ-
ity.18 One of the major tasks now needing to be addressed in this
field is to define the molecular details of the downstream signaling
pathways controlled by PKCs. We adopted a candidate approach
for this study that is based on the observation that one known
substrate for PKC is PKD, which had been shown previously to be
expressed in platelets and (using pharmacologic approaches) to be
regulated downstream of PKC.9
In this study, we used 2 recently generated, genetically targeted
mice to define a role for PKDs in platelets.9 First, a gene-trapped
PKD2/ mouse was used to define the expression profile of the
PKDs in mouse platelets and to overcome limitations of antibodies
for Western blotting. Second, a knock-in mouse replacing expres-
sion of WT PKD2 with a double point mutant, PKD2Ser707Ala/
Ser711Ala (PKD2SSAA/SSAA), was used to define how PKD2 is
regulated by upstream PKCs and to define the downstream
functions of PKD2. The data indicate that mouse platelets express
2 isoforms of PKD, PKD2 and PKD3, but not PKD1. However, of
these, PKD2 but not PKD3 activity was increased upon agonist
stimulation. Activation of PKD2 was shown to be entirely down-
stream of PKC, because no activation was detectable in the
PKD2SSAA/SSAA mutant, where PKC phosphorylation regulatory Ser
have been mutated to Ala. The classical PKC isoforms, PKC and
PKC, but not the novel isoforms PKC or PKC, were shown to
lie upstream of PKD2. Functionally, PKD2SSAA/SSAA platelets
partially phenocopy the deficits seen in the PKC/ platelets we
have described previously,2,7 suggesting that PKD2 is an important
effector for some, but not all, events downstream of PKCs in
platelets. In particular, this study has defined PKD2 as a major
effector and mediator of dense granule secretion downstream of
PKC, and therefore as a regulator of thrombus formation.
The high degree of sequence similarity between the PKDs, and
in particular between PKD1 and PKD2, has caused problems with
generating reagents that specifically recognize the individual
isoforms. We therefore took advantage of the recently generated
PKD2/ mouse9 to use the anti-PKD1/2 antibody to define
expression of PKD1 and PKD2 in platelets. Our data clearly show
the absence of expression of PKD1 and the presence of expression
of PKD2 in mouse platelets, which is in agreement with a similar
expression profile in other blood cell types.9,14 PKD3 is sufficiently
distinct in sequence to allow the generation of a specific antibody,
and blotting also showed expression of this isoform in mouse
platelets (Figure 1).
Having defined the expression profile of the PKD family
members in platelets, we then proceeded to define their regulation
and functional role. Existing evidence from other cell types shows
that the major regulatory mechanism upstream of PKD is PKC, and
in lymphocytes there is clear evidence for activation by novel PKC
isoforms.19-21 There is also evidence that the classical PKC isoform,
PKC, may also activate PKD, as it does in VEGF-induced
endothelial cell proliferation.22 Our data show that only 1 of the
2 expressed isoforms of PKD in platelets, PKD2 but not PKD3, is
responsive to thrombin or CRP. In addition, the novel isoforms of
PKC expressed in platelets, PKC and PKC, do not positively
regulate the activity of PKD2, although the densitometry results
shown in Figure 1C reveal that the absence of PKC tends to
increase the agonist-dependent activation of PKD2 in response to
both thrombin and CRP. It is therefore possible that PKC is a
negative regulator of agonist-induced PKD2 activity. In addition,
although a possible role for the other novel isoforms, PKC and
PKC, cannot be excluded, the conventional isoform, PKC, acts
as an upstream regulator of PKD2, particularly for GPVI signals.
For CRP-induced activation (at low concentrations in particular),
this isoform of PKC plays a substantial role; however, for
thrombin, other mechanisms of PKD activation may be involved,
such as redundancy with other PKC isoforms (PKC, PKC,
or PKC).
Figure 4. Biogenesis of dense and -granules is not regulated by PKD2 activity.
Washed platelets from WT or PKD2SSAA/SSAA mice were examined by transmission
electron microscopy, and the number of dense granules (black arrows) and
-granules (white arrows) was quantified as described in “Electron microscopy.”
(A) Images of platelets from WT (left panel) or PKD2SSAA/SSAA (right panel) mice are
representative of 3 independent experiments. Original magnification was 19 000,
and the bar represents 500 nm. (B) Dense and -granules were counted per fields of
view (25-30 fields of view per section, 3 sections per preparation on average) and are
shown as means 	 SEM, n 
 3.
Figure 5. Deficient aggregation responses in platelets from PKD2SSAA/SSAA mice are rescued by exogenously added ADP. Washed platelets from WT and
PKD2SSAA/SSAA mice were stimulated with CRP (1.25 g/mL; A) or thrombin (0.065 units/mL; B) with or without the simultaneous addition of ADP (10M), and aggregation was
assessed turbidimetrically. Aggregation traces are representative of 6 independent experiments with similar results.
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Definitive evidence that PKCs are critical for PKD2 activation
was possible because of the generation of the PKD2SSAA/SSAA
knock-in mouse. The mutated sites Ser707Ala and Ser711Ala are
critical for PKD2 catalytic activity downstream of PKC activa-
tion.9,11 Generation of this mouse also allowed the analysis of the
role of the catalytic activity of PKD2 independently of the role of any
scaffolding function that this molecule may possess. PKD2SSAA/SSAA
platelets showed no activation, as judged by autophosphorylation
of Ser916, in response to agonist, and the data indicate that a
PKC-dependent route to PKD2 activation is the only mechanism
by which PKD2 may be activated. This is largely in agreement with
recent data for T lymphocytes,9 although in these cells there is still
a small residual activity of PKD2SSAA/SSAA, suggesting that in
lymphocytes there is additional activation of PKD through a
non-PKC-dependent route. Whether the ability of PKD to translo-
cate to the membrane is affected by mutation of the PKC-
dependent phosphorylation sites is not yet known.
Defining a role for PKDs has not been possible until recently,
with the emergence of novel genetically targeted mice.9,23 Pharma-
cologic dissection of PKD function is still problematic because of
the poor selectivity of the majority of PKD kinase inhibitors.24-27 In
particular, isoform-specific pharmacologic inhibition of PKD is
currently not possible. Therefore, the PKD2SSAA/SSAA mouse is an
essential tool for the analysis of function of PKD in platelets. The
marked reduction in platelet aggregation responses to submaximal
concentrations of CRP and thrombin in PKD2SSAA/SSAA platelets
paralleled the impaired thrombus formation in whole blood flowed
over a collagen-coated surface. The deficit in aggregation,
however, could be fully recovered by the exogenous addition of
ADP, suggesting that the defect in dense granule secretion of
ADP was responsible for the disruption to platelet aggregation.
Indeed, dense granule secretion was markedly suppressed in
PKD2SSAA/SSAA platelets compared with WT platelets, with an
approximately 50% reduction in ATP release. Ablation of PKD2
had an effect only on dense granule secretion, whereas release of
-granules remained unimpaired. This observation indicates that
PKD2 in platelets has a highly selective regulatory role, and
suggests that it is responsible only for some, not all, of the signaling
downstream of conventional PKCs.
The data here show that biogenesis of both dense and -gran-
ules remains intact in PKD2SSAA/SSAA platelets compared with WT,
according to estimation of granule numbers by electron micros-
copy. Therefore, the defect in dense granule secretion cannot be
explained by a change in granule numbers. There is already
evidence from other cell types that PKD may regulate vesicular
protein transport from the Golgi to the plasma membrane28 and
secretion processes. Sumara et al described PKD as a pivotal
regulator of insulin secretion from pancreatic  cells,29 and Ge et al
found that PKC-dependent PKD2 activation was an essential
mechanism for P-selectin surface expression in endothelial cells.12
Although ablation of PKD2 activity manifested itself in a
pronounced reduction in platelet dense granule secretion, integrin
IIb3 activation remained unaffected. There may be several
explanations for this. First, PKD has been shown to regulate
integrin function in other cell types, partly through a scaffolding
function that is independent of its kinase activity. For example,
PKD1 is known to regulate the vesicular transport and incorpora-
tion of V3 into focal adhesions,30 to associate with V3 to
regulate fibroblast migration,31 and to positively regulate 1
function via Rap1 activation in T cells.32 In addition, platelets use
PKC-independent, as well as PKC-dependent, pathways to integrin
activation via CalDAGGEFI and Rap1b.33 Second, the residual
release of dense granules could be sufficient to maintain full
integrin activation. It is possible that the ability of platelets to
exhibit normal aggregation responses to high agonist concentra-
tions, as well as normal adhesion in static and initial adhesion in
flow conditions, were the consequences of this unimpaired compo-
nent of dense granule release. It is noteworthy that in the flow
system of assessment of thrombus formation, the released ADP is
washed away rapidly by the flowing blood, which is not the case in
the static conditions used to measure the level of integrin activation
by flow cytometry in a tube. The difference between these
2 approaches may explain why platelet surface coverage in the flow
system was reduced in PKD2SSAA/SSAA compared with WT mice
(Figure 6), whereas there was no difference in integrin activation
(supplemental Figure 2A).
Some features, but not others, of PKD2SSAA/SSAA platelet
phenotype mimic those found in PKC/ and PKC/ mice. We
showed previously that PKC/ mice were characterized by
ablation of secretion of both - and dense granules, which
ultimately translated into impairment of in vitro and in vivo
Figure 6. PKD2SSAA/SSAA mice display reduced throm-
bus formation in vitro but have normal tail-bleeding
responses. Heparin/PPACK-anticoagulated blood from
WT or PKD2SSAA/SSAA mice was passed over collagen
(shear rate 1000/s). (Ai) Representative phase-contrast
images after 4 minutes of flow. Scale bars represent
20 m. (ii) Platelet coverage of coated surfaces was
quantified and the mean surface area 	 standard error of
the mean is shown for 3 independent experiments.
*P  .05. (B) Mice were anesthetized and a transverse
incision made with a scalpel at a position where the
diameter of the tail was 2.25-2.5 mm. The tail was
immersed in normal saline (37°C) in a hand-held test
tube. The time from incision to cessation of bleeding was
recorded, and mean times are shown as horizontal bars.
No significant difference was seen comparing WT mice
with PKD2SSAA/SSAA mice (n 
 10-14).
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thrombus formation.2 Similarly, PKC-deficient mice also demon-
strate a reduction in thrombus formation under flow conditions in
vitro.7 PKD2 therefore represents a downstream effector of the
classical PKC isoforms in platelets, in particular PKC, for signals
downstream of GPVI.
In summary, we have shown that PKD2 plays a major role in the
selective regulation of platelet dense granule secretion, aggrega-
tion, and in vitro thrombus formation, thus representing a major
component of the pathway occurring downstream of PKC. The
central findings reveal a high degree of specialization of PKD2,
which regulates dense granule but not -granule platelet secretion.
PKD is implicated in a variety of disease-related states. Increasing
evidence points to PKD in the regulation of signaling pathways in
the cardiovascular system, particularly in the processes of myocar-
dial contraction, hypertrophy, and remodeling.34 PKD is responsive
to physiologically important stimuli in endothelial cells, vascular
smooth muscle cells, and platelets.13,22,35 PKD activity in general
and PKD2 in particular appear to guide the processes commonly
associated with atherosclerosis, such as endothelial cell migration,
proliferation, induction of proinflammatory cytokines, and mono-
cyte adhesion.36-38 Many of these cellular actions of PKD2 have
also been identified as critical points of control by PKC,39 making
it plausible that the fundamentally important pathophysiologic
functions of PKC, including its atherosclerosis-related prothrom-
botic characteristics,40-42 are executed at least partially by PKD2.
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